1. Introduction {#s0005}
===============

Type 2 diabetes mellitus (T2DM) is thought to be a multifactorial disease and both genetic and acquired factors contribute to its pathogenesis. Identification of the susceptibility genes for type 2 diabetes mellitus thus may lead to primary prediction of the disease ([@bb0060]). In most patients, T2DM results from genetic changes therefore it is helpful to identify the population with genetic predisposition and to protect them from exposure to environmental risks ([@bb0045]) as the environmental factors play an important role in favoring or delaying the expression of the disease.

Estrogen is a steroid hormone that influences many physiological processes, which include female reproduction, cardiovascular control, and bone integrity. Estrogen also exerts beneficial systemic effects on lipoprotein and antioxidant metabolism ([@bb0065]).

Therefore there is some evidence that estrogen plays a role in a combination of physiologic and metabolic disorders including insulin resistance, dyslipidemia, hypertension and excessive fat accumulation ([@bb0055; @bb0085]).

Due to its lipophilic characteristic, estrogen diffuses through plasma membrane and binds to its receptor (ER), a member of the nuclear receptor superfamily located in the nucleus and cytoplasm forming an estrogen/ER complex. This complex binds to estrogen response element sequences in the promoter region of estrogen responsive genes resulting in recruitment of co regulatory proteins (co-activators or co-repressors) to the promoter and gene expression regulation ([@bb0130]). Therefore, ERs are key components in the physiological effect of circulating estrogen as well as other metabolic and physiological processes ([@bb0020]).

ESRα gene encompasses 140 kb of DNA composed by eight exons, encoding a 595 amino acids protein with a molecular weight of about 66 KDa. The first intron of a gene, like the promoter, usually contains a larger number of regulatory sequences than other introns. Several single nucleotide polymorphisms (SNPs) have been identified on ESRα and some of them were associated with either an increased or a decreased risk of various diseases ([@bb0050]).

The best characterized SNPs of ESRα are the c454-397T\>C and c454-351A\>G site polymorphisms, both located in the first intron. These polymorphisms are 397 and 351 bp upstream of exon 2 and have been described by the name of detecting restriction enzyme, PvuII or XbaI, or their reference ID numbers, rs2234693 and rs9340799, respectively ([@bb0010]).

The PvuII and XbaI SNPs of the ESRα gene were found to be associated with several estrogen-dependent characteristics such as the onset of menopause ([@bb0175]), coronary reactivity ([@bb0075]), lumbar spine bone mineral density (BMD), vertebral bone area and vertebral fracture risk in post-menopausal women ([@bb0170]), as well as blood pressure ([@bb0140]) and lipid profile ([@bb0115]).

Also, various pathological conditions, including cardiovascular disorders ([@bb0070]), severe pre-eclampsia ([@bb0120]) and venous miscarriage ([@bb0155]) have been described. A possible functional mechanism attributed to PvuII and XbaI polymorphisms includes a change of ESRα gene expression by altering the binding of transcription factors ([@bb0010]).

The prevalence of T2DM and associated traits such as obesity, dyslipidemias, and hypertension in the overall population has become a worldwide challenge for health care system ([@bb0045]).

This study aimed both to evaluate the ESRα gene polymorphisms (PvuII and XbaI) in type 2 diabetic Egyptian women and to correlate the lipid profile (serum cholesterol, triglycerides, LDL and HDL) changes with ESRα gene polymorphism.

2. Patients and methods {#s0010}
=======================

2.1. Study population {#s0015}
---------------------

This study includes ninety (obese and non-obese) postmenopausal women with T2DM and forty non diabetic (obese and non-obese) controls. All subjects were Egyptians of the same ethnic group selected from outpatient clinic in Minia Hospital University aged 51--70 years, non-smokers, not consanguineous, and had no significant liver damage or renal dysfunction. Diagnosis of type 2 diabetes mellitus was based on [@bb0185]. Individuals with fasting blood glucose (FBG) ≥ 125.9 mg/dl were considered as having diabetes, while individuals with FBG \< 100.7 mg/dl were considered non-diabetic. Others with borderline values (125.9 mg/dl \> FBG ≥ 100.7 mg/dl) were excluded from the study. Patients and control subjects have no history of a sex-hormone-dependent disease and never received hormone replacement therapy.

The present study was conducted according to the principles of the Declaration of Helsinki, and all the participants provided written informed consent following a protocol approved by Minia University Research Ethics Committee. Body mass index (BMI) was measured for all the subjects.

2.2. Biochemical analysis {#s0020}
-------------------------

Peripheral blood was collected from the patients and control after a 12-h fasting on plain tubes, fluoride tube for fasting blood glucose and ethylenediaminetetraacetic acid (EDTA) tubes. The portion collected on EDTA tubes were divided into two aliquots; the first one was used for estimation of glycated hemoglobin (HBA~1~C) and the later were stored at-20 °C for DNA extraction. (HBA~1~C) was measured by TC MATREX analyzers using the kit supplied from TECO DIAGNOSTICS (USA) using (HBA~1~C) reagent 1, 2a, 2b and two hemolysis liquid reagents. The serum was separated and used for assessment of the following parameters: FBG was assayed enzymatically using kit supplied by (Biomed, Germany). Total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), and triglyceride (TG) levels were determined by standard methods using commercial kits from (Biomed, Germany). Low density lipoprotein-cholesterol (LDL-C) was calculated according to the Friedewald formula ([@bb0035]).

2.3. Genomic DNA extraction and genotyping {#s0025}
------------------------------------------

Genomic DNA was extracted from whole blood using the established protocol for DNA extraction from blood cells ([@bb0105]).

The PvuII and XbaI polymorphisms of ERα were analyzed by polymerase chain reaction restriction fragment length Polymorphism (PCR-RFLP) ([@bb0015]).

A 119 bp DNA fragment that contains two polymorphic sites was amplified using forward and reverse primers 5′-CTGTGTTGTCCATCACTTCATC-3′ and 5′-CCATTAGAGACCAATGCTCATC-3′. PCR was performed through 30 cycles by the following steps: denaturation at 95 °C for 60 s; annealing at 52 °C for 30 s; and extension at 72 °C for 30 s. The PCR product was digested with restriction enzyme PvuII, Xba1 (BioLabs, USA) at 37 °C for 16 h. The digested PCR products applied to a 2.5% agarose gel and stained with ethidium bromide. For PvuII, the homozygous variant TT produced two fragments 78 and 41 bp (indicate the presence of restriction site) while heterozygote TC produced three fragments of 119 and 78 bp and 41. The homozygous CC produced one fragment of 119 bp (represent the absence of restriction site). For XbaI the homozygous variant AA produced two fragments 88 and 31 bp (indicate the presence of restriction site) when heterozygote AG produced three fragments of 119, 88, and 31 bp and GG produced one fragment of 119 bp (represent the absence of restriction site). Representative samples were confirmed by sequencing. Samples were sequenced in MACROGEN lab technology.

2.4. Statistical analysis {#s0030}
-------------------------

Data entry and analysis were all done using software SPSS version 13. Quantitative data were presented by mean and standard deviation, while qualitative data were presented by frequency distribution. Chi Square used to test the significant difference for proportion and calculation of Odds ratio, and one way ANOVA test followed by the Tukey\'s test for multiple comparison. The genotypic and allelic frequencies were assessed using the Hardy--Weinberg equilibrium. The probability of less than 0.05 was used as a cut off point for all significant tests.

3. Results {#s0035}
==========

3.1. Demographic and clinical variables {#s0040}
---------------------------------------

The demographic and biochemical parameters of the T2DM patients and their age-matched controls are summarized in ([Table 1](#t0005){ref-type="table"}). The average age of obese and non-obese patients with diabetes were 59.4 ± 4.3 and 56.4 ± 4.2, respectively and in controls were 55.8 ± 2.9 and 56.3 ± 3.1, no significant difference between the four groups was found when analyzed by ANOVA. In comparison with the control groups and T2DM patients showed a significant increase in serum TG, TC, LDL-C, fasting blood glucose and HBA~1~C levels.

3.2. Genotypes and allele frequencies {#s0045}
-------------------------------------

The genotype distribution and the allele frequencies among the control and T2DM patients are shown in ([Table 2](#t0010){ref-type="table"}). The frequencies of TT, TC, and CC genotypes in control group were 37.5%, 47.5%, 15%, while in T2DM patients were 26.7%, 54.4%,18.9% respectively showing presence of significant difference and represent high risk factor among patients who carry heterozygous and homozygous polymorphic gene TC, CC (OR = 1.3, CI: 0.62--2.7; OR = 1.1, CI: 0.47--3.6; P = 0.01,0.04). The frequencies of AA, AG, and GG genotypes in control group were 50%, 37.5%, 12.5%, while in T2DM patients were 43.3%, 37.8%, 18.9% respectively showing a risk factor among patients who carry G allele in homozygous and heterozygous form (OR = 1.6, CI: 0.55--4.7; OR = 1.01, CI: 0.46--2.1; p = 0.03,0.7).

3.3. T → C polymorphism (PvuII) ([Fig. 1](#f0005){ref-type="fig"}) {#s0050}
------------------------------------------------------------------

Carriers of C allele in the homozygous or heterozygous form (CC or TC genotypes) were associated with highly significant increase in Fasting blood glucose, triglycerides, total cholesterol and LDL-C (p = 0.01), (p = 0.001), (p = 0.002) and (p = 0.01) respectively, but there was a significant decrease in the level of HDL-C (p = 0.002). ([Table 3](#t0015){ref-type="table"}).

3.4. A → G polymorphism (XbaI) ([Fig. 2](#f0010){ref-type="fig"}) {#s0055}
-----------------------------------------------------------------

Fasting blood glucose, Triglyceride and LDL-C showed an increase among patients who carry G allele in the heterozygous and homozygous (AG, GG genotypes) as there was a highly significant increase in these parameters (p = 0.03), (p = 0.001) and (p = 0.04) respectively while there was no significant difference in total cholesterol and HDL-C ([Table 4](#t0020){ref-type="table"}).

Our results were confirmed by sequencing [Fig. 3](#f0015){ref-type="fig"}(A, B).

4. Discussion {#s0060}
=============

Type 2 diabetes mellitus (T2DM) is a public health problem in the world with a high prevalence which is the most noticeable disease in developing countries ([@bb0125]) so it is helpful to identify the population with genetic predisposition and to protect them from exposure to environmental risks ([@bb0045]). Different studies showed that estrogen can inhibit the deduction of insulin dependent diabetes, modulates insulin secretion, regulates calcium signals through plasma membrane receptors, and regulates K-ATP channel activity ([@bb0165; @bb0190]). Also, Estrogen has been implicated in the suppression of hepatic glucose production and the protection of B-cell ([@bb0100]).

In this study, PvuII polymorphism in 51--70 years\' women from Minia city, Egypt was examined. Our data showed that there is an increase in the percentage of heterozygous and homozygous TC and CC alleles in diabetic patients compared to control group suggesting that C allele may increase the risk of incidence of DM.

Although a study of 49 Caucasians with type 2 diabetes mellitus showed no significant difference between type 2 diabetic group and control group in the allelic frequency of PvuII of ESRα ([@bb0060]) however African--Americans and European-Americans study ([@bb0145]) showed a significant association of ESRα gene PvuII polymorphisms and type 2 diabetes mellitus.

The position of PvuII in an intron, near the gene promoter suggests a possible role in either transcription regulation or mRNA processing and stability ([@bb0010]). So in a previous study it was found that CC genotype at PvuII predicted lower ESRα mRNA levels in patients prefrontal cortex ([@bb0180]). Also PvuII polymorphism may affect the splicing of ESRα mRNA, resulting in the alteration of protein expression ([@bb0060]) or production of ESRα isoforms that have different properties than the full-length gene product ([@bb0020]).

The C allele contains a potential binding site for myeloblast transcription factors that can amplify transcription of a downstream reporter as much as tenfold in vitro. The binding site for myeloblastosis expression is responsive to estrogen activation (bound to ER), resulting in a signal-altering system with differential responses ([@bb0060]). A previous report confirmed the association between the C allele of the pvuII polymorphism and the absence of expression of the ESRα gene ([@bb0080]).

It is clear that estrogen affects the lipoprotein metabolism in many potential beneficial ways ([@bb0030]). Although an Indonesian study in Javanese population showed that PvuII allele C has been associated with lower small LDL concentration also that allele in this study was associated with no increased risk for suffering type 2 diabetes mellitus ([@bb0005]) however a Chinese study suggested that the PvuII polymorphism of ESRα is associated with type 2 diabetes and related to increased serum lipid levels in postmenopausal women ([@bb0060]).

Our study was in agreement with the last one as lipid profile assay shows a significant increase among patients group who carry C allele in the homozygous or heterozygous form (CC or TC genotypes) as there was a highly significant increase in triglycerides, total cholesterol and LDL-C while there was a highly significant decrease in the level of HDL-C, that high serum lipid can increase the risk of T2DM in healthy group ([@bb0110]). These results may explain several studies which have shown a positive relationship of ESRα PvuII C allele with a higher risk of atherosclerosis and stroke in men ([@bb0075; @bb0150]) and familial hypercholesterolemia ([@bb0090]) as ESR-α can indirectly influence many molecular signaling mechanisms related to risk factors for cardiovascular disease (CVD) via co-modulation with important factors such as insulin receptor, insulin-like growth factor receptor, and peroxisome proliferator-activated receptor ([@bb0020]).

For XbaI polymorphism, our study showed that AG and GG genotype was significantly more frequent in type 2 diabetes mellitus women than control representing high risk factor among patients. A previous study of Caucasians patients with type 2 diabetes mellitus showed a significant difference between type 2 diabetes mellitus group and control group of ESRα in the allelic frequency of XbaI ([@bb0060]) also Indonesian study in Javanese population showed that XbaI polymorphism is associated with increased susceptibility of type 2 DM in Javanese menopausal women ([@bb0005]).

A-allele as mayor allele in this study correlated with studies in European-American population ([@bb0040]). Among Europeans G homozygotes was found to have lower insulin secretory capacity ([@bb0165]) leading them to conclude that the G allele may play a role in the pathogenesis of Type 2 diabetes.

[@bb0160] and his colleagues are in agree with our study that G allele in patients were higher than those in healthy subjects, showed a significant association of ESRα gene XbaI polymorphisms and type 2 diabetes mellitus.

In our study, triglyceride and LDL-C showed significant increase among patients who carry G allele especially in the heterozygous (AG genotypes) while there is no significance difference in total cholesterol and HDL-C and this was in agreement with several studies conducted in Hungary, Japan, the United States and Italy found that the GG genotype was associated with higher total cholesterol and LDL-C and increased risk of CAD and venous thrombosis ([@bb0090; @bb0025; @bb0095; @bb0115]). However other studies found no association between any cardiovascular risk factor and the G allele this may be due to what previously reported that the G allele may have different consequences depending on the person\'s age, gender, and hormonal status ([@bb0020]) so in a previous study it was found that among postmenopausal women, the G allele was beneficial, being associated with lower BMI, percentage body fat and waist circumference ([@bb0135]).

This study found that that PvuII and XbaI polymorphism of ESRα increases susceptibility to type 2 diabetes mellitus in Egyptian postmenopausal women. ESRα variants may also affect serum lipid metabolism, which might provide a mechanism connecting ESRα to type 2diabetes so further studies with larger sample sizes are required to replicate these findings. Also investigation of SNPs of ESRα polymorphisms other than PvuII and XbaI should also be addressed in future studies.
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![PCR-RFLP analysis on 2.5% agarose gel representing the PvuII genotypes.](gr1){#f0005}

![PCR-RFLP analysis on 2.5% agarose gel representing the XbaI genotypes.](gr2){#f0010}

![Sequencing confirmed our result for polymorphism as it shows a different base in the heterozygous and homozygous allele (A sample shows TC and GG allele, B sample shows TT and AG allele). Sequence of restriction cut for PvuII: CAGC*T*G and for XbalI: TCTA*G*A.](gr3){#f0015}

###### 

Demographic and biochemical characteristics of study subjects.

                       Control        T2DM patients   P value                       
  -------------------- -------------- --------------- -------------- -------------- ----------------------------------------
  Age (years)          56.3 ± 3.1     55.8 ± 2.9      56.4 ± 4.2     59.4 ± 4.3     0.4
  FBG (mg/dl)          90.7 ± 11.02   91.6 ± 4.4      160.6 ± 24.1   203.5 ± 44.3   0.001[⁎](#tf0005){ref-type="table-fn"}
  HBA~1~C              4.8 ± 0.6      4.8 ± 0.6       8.2 ± 0.9      8.9 ± 1.3      0.001[⁎](#tf0005){ref-type="table-fn"}
  Body mass(kg/m^2^)   24.2 ± 1.1     34.1 ± 1.9      26.2 ± 2.1     35.9 ± 2.6     0.001[⁎](#tf0005){ref-type="table-fn"}
  TC (mg/dl)           106.4 ± 28.4   214.7 ± 26.7    198.6 ± 25.3   236.1 ± 44.7   0.002[⁎](#tf0005){ref-type="table-fn"}
  HDL-C (mg/dl)        46.2 ± 6.2     39.1 ± 7.5      44.8 ± 7.3     38.7 ± 7.6     0.001[⁎](#tf0005){ref-type="table-fn"}
  TG(mg/dl)            91.2 ± 7.3     166.9 ± 9.5     201.2 ± 26.8   225.3 ± 41.3   0.001[⁎](#tf0005){ref-type="table-fn"}
  LDL-C (mg/dl)        43.1 ± 5.5     142.2 ± 32.8    113.1 ± 29.4   152.4 ± 44.5   0.001[⁎](#tf0005){ref-type="table-fn"}

Data are presented as mean ± SD. Comparisons between groups were analyzed by ANOVA test.

Statistically highly significant.

###### 

Allele frequencies and genotypes distribution of ER-α gene PvuII and XbaI polymorphisms in control and T2DM patients.

             Control n (%) (n = 40)   T2DM n (%) (n = 90)   OR (95% CI)       P value
  ---------- ------------------------ --------------------- ----------------- ---------------------------------------
  *PvuII*                                                                     
  T allele   49(61.3%)                97(53.9%)                               
  C allele   31(38.7%)                83(46.1%)             1.3(0.5--2.3)     0.02[⁎](#tf0010){ref-type="table-fn"}
  TT         15(37.5%)                24(26.7%)             Reference         
  TC         19(47.5%)                49(54.4%)             1.3(0.62--2.7)    0.01[⁎](#tf0010){ref-type="table-fn"}
  CC         6(15%)                   17(18.9%)             1.1(0.47--3.6)    0.04[⁎](#tf0010){ref-type="table-fn"}
                                                                              
  *XbaI*                                                                      
  A allele   55(68.7%)                107(59.4%)                              
  G allele   25(31.3%)                73(40.6%)             1.08(0.6--1.9)    0.04[⁎](#tf0010){ref-type="table-fn"}
  AA         20(50%)                  34(37.8%)             Reference         
  AG         15(37.5%)                39(43.3%)             1.01(0.46--2.1)   0.7
  GG         5(12.5%)                 17(18.9%)             1.6(0.55--4.7)    0.03[⁎](#tf0010){ref-type="table-fn"}

Comparisons were performed by the chi-square test; (CI) = confidence interval; OR = odds ratio. P value of odds ratio.

Statistically significant. P \< 0.05.

###### 

The relationship between PvuII genotypes and different clinical parameters among diabetic study population.

                              PvuII                                                           
  --------------------------- -------------- ------------------------------------------------ ------------------------------------------------
  Age                         57.3 ± 3.8     57.6 ± 5                                         57.6 ± 7.1
  FBG (mg/dl)                 170.9 ± 21.7   189.5 ± 33.8[⁎](#tf0015){ref-type="table-fn"}    179.8 ± 42[⁎](#tf0015){ref-type="table-fn"}
  BMI                         28.1 ± 2.2     31.4 ± 2.5                                       31.2 ± 2.1
  Total cholesterol (mg/dl)   185.7 ± 12.5   224.8 ± 36.5[⁎⁎](#tf0020){ref-type="table-fn"}   229.4 ± 33.1[⁎⁎](#tf0020){ref-type="table-fn"}
  HDL-C(mg/dl)                46.9 ± 5.4     38.3 ± 7[⁎⁎](#tf0020){ref-type="table-fn"}       39.6 ± 6.5[⁎⁎](#tf0020){ref-type="table-fn"}
  Triglycerides (mg/dl)       184.3 ± 11.9   225 ± 33.5[⁎⁎](#tf0020){ref-type="table-fn"}     216 ± 31.6[⁎⁎](#tf0020){ref-type="table-fn"}
  LDL-C(mg/dl)                99.7 ± 17.2    139.6 ± 37.7[⁎](#tf0015){ref-type="table-fn"}    146.5 ± 35.1[⁎](#tf0015){ref-type="table-fn"}
  HBA~1~C (%)                 8 ± 0.9        8.5 ± 1.2                                        8.3 ± 1.4

Data are presented as mean ± SD. comparisons were performed by one way ANOVA test followed by the Turkey\'s test for multiple comparison.

Indicates significant difference from carriers of TT at P \< 0.05.

Highly significance.

###### 

The relationship between XbaI genotypes and different clinical parameters among diabetic study population.

                              XbaI                                                          
  --------------------------- -------------- ---------------------------------------------- -----------------------------------------------
  Age                         57.4 ± 4.5     57.5 ± 3.3                                     58 ± 4.3
  FBG (mg/dl)                 160.4 ± 25.9   188.7 ± 37[⁎](#tf0025){ref-type="table-fn"}    181 ± 38.7[⁎](#tf0025){ref-type="table-fn"}
  BMI                         29.6 ± 2.7     31.3 ± 2.2                                     31.1 ± 2
  Total cholesterol (mg/dl)   197.6 ± 22.1   227.1 ± 34.7                                   216.1 ± 36.6
  HDL-C(mg/dl)                46.3 ± 4.9     38.8 ± 6                                       42.4 ± 6.3
  Triglycerides (mg/dl)       181.9 ± 10.5   225 ± 34.1[⁎⁎](#tf0030){ref-type="table-fn"}   216.3 ± 25[⁎⁎](#tf0030){ref-type="table-fn"}
  LDL-C(mg/dl)                115.1 ± 33.8   143.1 ± 36[⁎](#tf0025){ref-type="table-fn"}    130.6 ± 34.6[⁎](#tf0025){ref-type="table-fn"}
  HBA~1~C (%)                 8.1 ± 1.1      8.6 ± 1.2                                      8.1 ± 1.2

Data are presented as mean ± SD. comparisons were performed by one way ANOVA test followed by the Turkey\'s test for multiple comparison.

Indicates significant difference from carriers of AA at P \< 0.05.

Highly significance.
